Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa

Stock Information for Ocugen, Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Ocugen, Inc.

Ocugen to Provide Business Update and Third Quarter 2026 Financial Results on November 4
Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa
Did Ocugen, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate
Ocugen to Participate in Upcoming Scientific Conferences
Ocugen to Participate in Upcoming October Investor and Industry Conferences
Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit
Ocugen CEO to Present at NobleCon21-Noble Capital Markets' Twenty-First Annual Emerging Growth Equity Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.